What attenuation strategies do you offer for Lm-based cancer vaccines?

We support a range of attenuation approaches including classic virulence gene deletions (ΔactA, ΔactA/ΔinlB), the LADS (Live Attenuated Double Substitution) platform, KBMA (killed but metabolically active) strains, and Lm-RIID configurations. Each option is evaluated for intracellular growth attenuation, genetic stability, and retained capacity to prime TAA-specific CD8+ T cells before final selection.

Which syngeneic tumor models do you recommend for Lm vaccine efficacy studies?

We routinely employ CT26 (colorectal), B16-F10 and B16-OVA (melanoma), TC-1 (HPV16-E7+), and 4T1 (mammary carcinoma) models. For Lm-OVA proof-of-concept, B16-OVA is the gold standard pairing with SIINFEKL-H-2Kb tetramer monitoring. Custom tumor lines expressing your TAA can be developed upon request.

How do you address the issue of immunodominant Lm epitopes competing with TAA responses?

We employ two complementary strategies: epitope engineering through anchor residue substitutions to enhance TAA peptide-MHC binding stability, and heterologous prime-boost regimens where the TAA is first introduced via a non-Lm platform to establish TAA-specific memory before Lm boosting.

Can you evaluate Lm vaccines in combination with immune checkpoint inhibitors?

Yes. Lm vaccination naturally upregulates PD-L1 in the tumor microenvironment, creating rationale for anti-PD-1/PD-L1 combination. We design parallel arm studies with endpoints including tumor growth inhibition, overall survival, TIL density and composition, and systemic cytokine profiling.

Preclinical Listeria-Based Cancer Vaccine Design & Construction

Q: What quality control assays do you perform on recombinant Lm vaccine batches?

Each batch undergoes colony PCR for gene deletion and cassette integration, Western blotting for TAA-LLO secretion, CFU enumeration, intracellular growth kinetic assays and plaque size reduction for attenuation phenotype confirmation, and sterility testing. A certificate of analysis is provided with every batch.

Preclinical Listeria-Based Cancer Vaccine Design & Construction

Creative Biolabs is a leader in preclinical cancer vaccine development, offering a specialized, end-to-end platform for the design and construction of attenuated Listeria monocytogenes-based immunotherapeutics. L. monocytogenes is a Gram-positive facultative intracellular bacterium with a unique ability to escape the phagolysosome and enter the host cell cytosol—an attribute that makes it one of the most potent live bacterial vectors for delivering tumor-associated antigens (TAAs) directly into the MHC class I antigen presentation pathway. By engineering attenuated strains that secrete TAA-LLO (listeriolysin O) fusion proteins under the control of the master virulence regulator PrfA, our team constructs vaccine candidates that elicit robust, antigen-specific CD8+ cytotoxic T lymphocyte (CTL) responses while reshaping the immunosuppressive tumor microenvironment. From backbone selection and virulence gene deletion to comprehensive in vitro and in vivo potency validation, we provide a fully integrated service designed to bridge the gap between bacterial vector engineering and translational cancer immunotherapy.

Why Listeria monocytogenes Is a Powerful Vaccine Vector for Cancer

Cytosolic Antigen Delivery with Built-in Adjuvant Activity

L. monocytogenes (Lm) selectively infects professional antigen-presenting cells (APCs)—macrophages, neutrophils, and dendritic cells. Following phagocytosis, the bacterium deploys its pore-forming virulence factor LLO to rupture the phagolysosomal membrane, releasing itself and its secreted protein cargo into the cytosol. This phagosome-to-cytosol transition is the defining feature that distinguishes Lm from other bacterial vectors: antigens delivered via Lm are processed through the ubiquitin-proteasome pathway and presented on MHC class I molecules, directly priming CD8+ CTLs. Meanwhile, pathogen-associated molecular patterns (PAMPs) from the bacterium provide potent innate adjuvant signaling, inducing IL-12, IL-6, and TNFα secretion and driving DC maturation without the need for exogenous adjuvants.

Key Advantage — Dual MHC Presentation:
While Lm is renowned for MHC class I-restricted CTL priming, the secreted antigen pool can also be taken up by bystander APCs and cross-presented on MHC class II molecules, enabling coordinated CD4+ helper T cell activation. This dual pathway engagement is essential for durable antitumor memory.

Core Preclinical Challenges We Solve:
Designing safe, immunogenic attenuated strains (ΔactA, ΔactA/ΔinlB, LADS, KBMA).
Overcoming immunodominant Lm epitopes that compete with TAA-specific responses.
Optimizing TAA-LLO fusion cassettes for stable secretion and proteasomal processing.
Quantifying Lm-mediated TME remodeling (Treg, MDSC, and effector cell profiling).

Lm vs. Other Bacterial & Viral Vectors: A Preclinical Perspective

Key Comparison	Other Bacterial / Viral Vectors	Listeria monocytogenes Vector
Antigen Access to MHC-I Pathway	Mostly restricted to phagosomal processing; cross-presentation required.	Direct LLO-mediated phagosome escape; efficient cytosolic delivery.
Innate Immune Activation	Often requires co-administered adjuvants or TLR agonist supplementation.	Built-in PAMP-driven adjuvant activity (IL-12, TNFα, NO).
Pre-existing Vector Immunity	Neutralizing antibodies common for adenovirus, HSV-1, measles virus.	Low seroprevalence; minimal pre-existing neutralizing immunity.
Genomic Integration Risk	Viral vectors (LV, AAV) carry insertional mutagenesis risk.	No genomic integration; antibiotic-clearable if needed.

End-to-End Listeria Vaccine Design & Preclinical Characterization

Our preclinical services are organized into six modular packages that cover the complete Lm vaccine development pipeline. Every module can be customized—from the choice of attenuation strategy to the specific TAA-LLO fusion architecture—to align with your target indication and antigen selection.

Backbone

Attenuated Strain Engineering & Selection

Selection and construction of the optimal attenuated Lm backbone for your project.

Virulence Gene Deletion: ΔactA, ΔactA/ΔinlB, or custom multi-gene deletions.
Advanced Platforms: LADS (Live Attenuated Double Substitution), KBMA (killed but metabolically active), and Lm-RIID.
Safety Verification: In vitro intracellular growth kinetics and plaque size reduction assays.
Genetic Stability: Serial passage analysis confirming attenuation phenotype retention.

Cassette

TAA-LLO Fusion Cassette Design & Cloning

Custom molecular engineering of the antigen expression and secretion module.

Fusion Architecture: Design of truncated LLO (non-hemolytic) fused to single or multi-epitope TAA sequences.
PrfA-Regulated Expression: Placement under the endogenous PrfA-dependent hly promoter for intracytosolic induction.
Signal Sequence Optimization: SecA2-dependent secretion tag engineering for efficient protein export.
Multi-Cassette Configurations: Dual or triple TAA-LLO operons for polyvalent vaccine constructs.

Production

Recombinant Lm Production & Quality Control

Scalable culture of recombinant Lm strains with rigorous identity and purity testing.

BHI Broth Culture: Brain-heart infusion-based growth under selective antibiotic pressure.
Colony PCR Screening: Confirmation of gene deletion loci and TAA cassette integration.
Western Blot Verification: Detection of secreted TAA-LLO fusion protein in culture supernatant.
Viability & CFU Determination: Colony-forming unit quantification for precise dosing.

Validation

In Vitro Infection & Antigen Presentation Assays

Functional validation of Lm infection, phagosome escape, and antigen processing in APCs.

BMDC Infection Kinetics: Gentamicin protection assay measuring intracellular CFU at 1, 4, and 8 h post-infection.
Phagosome Escape Assay: LLO-dependent cytosolic access monitored by fluorogenic reporter systems.
MHC-I Presentation: SIINFEKL-H-2Kb surface staining in Lm-OVA-infected DCs by flow cytometry.
DC Maturation Panel: Upregulation of CD80, CD83, CD86, and MHC-II on infected BMDCs.

Immunology

Immunogenicity & T Cell Response Profiling

Comprehensive assessment of vaccine-elicited T cell immunity and TME remodeling.

ELISpot & ICS: IFN-γ ELISpot and intracellular cytokine staining for TAA-specific CD8+ T cell quantification.
In Vivo CTL Assay: Peptide-pulsed target cell clearance measurement following prime-boost vaccination.
Tetramer Staining: MHC class I tetramer-based enumeration of antigen-specific CD8+ T cells.
TME Profiling: Multiparametric flow analysis of Treg (FoxP3+), MDSC (Gr-1+CD11b+), and NK (NK1.1+) populations.

Efficacy

In Vivo Tumor Efficacy & Biodistribution

Preclinical tumor model testing with comprehensive pharmacodynamic and safety endpoints.

Syngeneic Tumor Models: CT26 (colorectal), B16-F10 (melanoma), TC-1 (HPV+), and 4T1 (breast) models.
Tumor Growth Monitoring: Caliper measurement of tumor volume with Kaplan-Meier survival analysis.
Biodistribution: CFU-based organ colonization profiling (liver, spleen, tumor) at serial time points.
Combination Therapy: Co-administration with immune checkpoint inhibitors for synergy evaluation.

Preclinical Listeria Vaccine Development Workflow

Phase 1 — Attenuation Strategy & Backbone Selection

We consult on the optimal attenuated Lm backbone based on your target indication and antigen characteristics. Options range from single-gene deletions (ΔactA) to double-deletion strains (ΔactA/ΔinlB) and advanced platforms such as LADS and KBMA. Each candidate is evaluated for intracellular growth attenuation, genetic stability, and retained immunogenicity before final selection.

Phase 2 — TAA-LLO Fusion Cassette Design & Molecular Cloning

The selected TAA sequence is codon-optimized and fused to a truncated, non-hemolytic LLO fragment. The expression cassette is placed under the endogenous PrfA-dependent hly promoter for intracytosolic induction upon host cell entry. Multi-epitope or polyvalent configurations are supported. Integration into the Lm chromosome or a stable plasmid vector is confirmed by PCR and sequencing.

Phase 3 — Recombinant Lm Culture & Quality Release

Recombinant Lm is cultured in BHI broth under selective conditions. We perform colony PCR to verify gene deletion and cassette integration, Western blotting for TAA-LLO secretion, and CFU-based viability quantification. Each batch is released with a certificate of analysis documenting identity, purity, and titer.

Phase 4 — In Vitro APC Infection & Antigen Presentation

Bone marrow-derived dendritic cells (BMDCs) are infected with recombinant Lm at defined multiplicities of infection. We assess intracellular growth kinetics, phagosome escape efficiency, surface MHC-I-peptide complex presentation, and DC maturation markers (CD80, CD83, CD86, MHC-II) by flow cytometry.

Phase 5 — In Vivo Immunogenicity & Tumor Protection Studies

Mice receive prime-boost vaccination with the recombinant Lm strain. We quantify TAA-specific CD8+ T cell responses by ELISpot, tetramer staining, and in vivo CTL assays. Tumor challenge experiments in syngeneic models (e.g., CT26, B16-F10, TC-1) assess protective efficacy, with serial tumor volume monitoring and survival analysis over 60–90 days.

Enabling Technologies for Listeria-Based Cancer Vaccines

PrfA-Regulated TAA-LLO Expression Platform

We engineer antigen expression cassettes under the control of the PrfA virulence regulon, ensuring that TAA-LLO fusion protein synthesis is triggered only upon host cell entry and cytosolic localization. This intracytosolic induction minimizes metabolic burden on the extracellular bacterium while maximizing antigen delivery to the MHC-I processing machinery precisely where it is needed.

Multi-Locus Attenuation & Safety Engineering

Our platform supports multiple attenuation modalities—ΔactA to eliminate actin-based intercellular spread, ΔinlB to reduce hepatocyte tropism, and amino acid substitution strategies (LADS) to fine-tune metabolic fitness. Each approach is validated through intracellular growth kinetic assays and plaque size reduction in fibroblast monolayers.

Integrated TME Remodeling & Immune Monitoring

Beyond CD8+ T cell readouts, we deploy multiparametric flow cytometry panels to quantify Lm-mediated changes in the tumor microenvironment—including Treg depletion, MDSC reduction, NK cell recruitment, and pro-inflammatory cytokine shifts (IL-12, IFN-γ, TNFα)—providing a holistic view of vaccine-induced antitumor immunity.

Why Choose Creative Biolabs for Lm Vaccine Development?

Deep Expertise in Bacterial Vector Biology

Our team has extensive hands-on experience with Lm virulence regulation, attenuation strategies, and intracellular life-cycle manipulation for preclinical vaccine design.

Flexible Attenuation & Expression Options

From classic ΔactA deletions to cutting-edge LADS and KBMA platforms, we offer the full spectrum of attenuation and antigen delivery strategies under one roof.

Comprehensive Preclinical Readout Panels

Our immunogenicity assessments go beyond ELISpot—we profile TME remodeling, memory T cell formation, and combination therapy synergy in relevant syngeneic tumor models.

Modular, Transparent Project Design

Every service module is independently selectable and fully customizable. You receive clear timelines, raw data access, and a dedicated project scientist for direct communication.

Research Insight: Optimizing Lm-Based Vaccine Design for Cancer

Key Preclinical Findings Guiding Current Vector Design

Attenuated Listeria monocytogenes has emerged as one of the most versatile live bacterial vectors for cancer immunotherapy, with over 30 clinical-stage programs and an extensive preclinical literature detailing its mechanisms and optimization strategies.

Comprehensive Review of Lm Vector Biology: The phagosome-to-cytosol transition mediated by LLO, combined with ActA-dependent intercellular spread, positions Lm uniquely among bacterial vectors for MHC class I-restricted antigen delivery. Virulence-attenuated strains retain potent adjuvant activity while eliminating pathogenicity, as reviewed by Ding et al.¹
Immunodominance as a Design Constraint: Flickinger et al. demonstrated that immunodominant Lm epitopes (LLO, p60, Mpl) can outcompete TAA-derived epitopes for MHC binding due to superior peptide-MHC complex stability. Epitope engineering through anchor residue substitution rescued TAA-specific CTL priming in a colorectal cancer model.²
Pyroptosis & Necroptosis Shape Durable Immunity: Olagunju et al. showed that caspase-1/11 and GSDMD deficiency—while impairing acute bacterial control—paradoxically enhanced long-lasting effector CD8+ T cell generation from Lm-OVA vaccination, revealing that host cell death pathway modulation can be leveraged to fine-tune vaccine durability.³
Memory T Cells as the Ultimate Vaccine Goal: A 2025 review by Olagunju et al. consolidates evidence that recombinant Lm vaccines excel at inducing functional memory T cell pools capable of long-term tumor surveillance, and highlights how vector design parameters—attenuation level, antigen secretion rate, and dosing schedule—collectively determine memory formation efficiency.⁴

Preclinical evaluation of Listeria monocytogenes-based cancer vaccine immunogenicity and tumor protection.

Fig.1 Mechanism by which Lm-based vaccines modulate the tumor microenvironment.^1,5

FAQs Regarding Listeria-Based Vaccine Services

We support a range of attenuation approaches tailored to your project's safety and immunogenicity requirements. These include classic virulence gene deletions (ΔactA and ΔactA/ΔinlB), the LADS (Live Attenuated Double Substitution) platform involving amino acid substitutions in essential metabolic enzymes, KBMA (killed but metabolically active) strains that retain adjuvant activity without replication, and Lm-RIID (recombinant induced intracellular death) configurations. Each option is evaluated for intracellular growth attenuation, genetic stability, and retained capacity to prime TAA-specific CD8+ T cells before final selection.

We routinely employ CT26 (BALB/c colorectal carcinoma), B16-F10 and B16-OVA (C57BL/6 melanoma), TC-1 (C57BL/6 HPV16-E7-expressing lung epithelial), and 4T1 (BALB/c mammary carcinoma) models. The choice depends on your TAA and MHC haplotype. For Lm-OVA proof-of-concept studies, we recommend B16-OVA as a gold-standard model that pairs directly with SIINFEKL-H-2Kb tetramer-based immune monitoring. We can also develop custom tumor lines expressing your TAA of interest upon request.

This is a well-recognized challenge. We employ two complementary strategies: (1) epitope engineering—introducing anchor residue substitutions in TAA epitopes to enhance peptide-MHC binding stability, as demonstrated to rescue subdominant epitope responses; and (2) heterologous prime-boost regimens where the TAA is first introduced via a non-Lm platform (e.g., DNA vaccine or peptide-pulsed DCs) to establish TAA-specific memory, followed by Lm boost to amplify the response while minimizing competition from primary Lm epitopes.

Each recombinant Lm batch undergoes a panel of quality release assays: colony PCR to confirm gene deletion loci and TAA cassette integration; Western blotting to verify TAA-LLO fusion protein secretion into culture supernatant; CFU enumeration with triplicate plating for precise dosing; intracellular growth kinetic assays and plaque size reduction in L2 fibroblast monolayers to confirm attenuation phenotype retention; and sterility testing. A comprehensive certificate of analysis is provided with every batch.

Yes. Lm vaccination naturally upregulates PD-L1 expression in the tumor microenvironment through IFN-γ-mediated signaling, creating a strong rationale for combination with anti-PD-1 or anti-PD-L1 checkpoint blockade. We design parallel arm studies comparing vaccine alone, checkpoint inhibitor alone, and the combination, with endpoints including tumor growth inhibition, overall survival, TIL density and composition, and systemic cytokine profiling. Radiotherapy combination protocols are also available upon request.

Vector based Vaccine Development Solutions

Adenovirus-Based Cancer Vaccine Design

Poxvirus-Based Cancer Vaccine Design

Alphavirus-Based Cancer Vaccine Design

Lentivirus-Based Cancer Vaccine Design

NDV-Based Cancer Vaccine Design

HSV-1-Based Cancer Vaccine Design

Measles Virus based Vaccine Development

Salmonella based Vaccine Development

Yeast based Vaccine Development

Arenavirus based Vaccine Development

Related Resources

Scientific References

Ding, Yi-Dan, et al. "Listeria monocytogenes: a promising vector for tumor immunotherapy." Frontiers in Immunology 14 (2023): 1278011.https://doi.org/10.3389/fimmu.2023.1278011
Flickinger, John C., Jr., et al. "T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C." Frontiers in Immunology 13 (2022): 855759.https://doi.org/10.3389/fimmu.2022.855759
Olagunju, Abolaji S., Andrew V. D. Sardinha, and Gustavo P. Amarante-Mendes. "Long-Lasting, Fine-Tuned Anti-Tumor Activity of Recombinant Listeria monocytogenes Vaccine Is Controlled by Pyroptosis and Necroptosis Regulatory and Effector Molecules." Pathogens 13, no. 10 (2024): 828.https://doi.org/10.3390/pathogens13100828
Olagunju, Abolaji Samson, et al. "Memory T Cells, Recombinant Listeria monocytogenes, and Cancer Vaccines." Frontiers in Bioscience-Landmark 30, no. 7 (2025): FBL36329.https://doi.org/10.31083/FBL36329
All references distributed under CC BY 4.0 International License.